Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03197584 2025-02-21

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Phase 1/2 Withdrawn

Gynecologic

Ovarian Neoplasms

NCT04034251 2025-02-03

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Phase 2 Completed

12 enrolled 18 charts

GastrointestinalGynecologic

Adenocarcinoma, Peritoneal Neoplasms, Stomach Neoplasms

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Phase 1/2 Completed

169 enrolled

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Phase 1 Completed

279 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT02009449 2024-11-15

IVY

Phase 1 Completed

353 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT05700656 2024-07-22

Galunisertib Combined With Capecitabine in Advanced CRC With PM

Phase 1/2 Recruiting

31 enrolled

GastrointestinalGynecologic

Peritoneal Neoplasms, Colorectal Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04508686 2021-01-29

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Phase 1 Unknown

20 enrolled

Gynecologic

Advanced Cervical Cancer

NCT00354601 2017-08-30

Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

Phase 2 Terminated

2 enrolled 7 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00039442 2017-08-24

Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer

Phase 2 Completed

21 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT00003704 2016-07-06

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

Phase 1 Completed

51 enrolled

GastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Testicular Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT00403429 2016-01-14

MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer

Phase 2 Completed

36 enrolled

Gynecologic

Ovarian Neoplasms

NCT01233505 2014-04-02

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Phase 1 Terminated

16 enrolled

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT00004012 2013-06-24

Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00016926 2013-05-27

Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Phase 2 Completed

Gynecologic

Uterine Cervical Neoplasms

NCT00006812 2013-04-11

Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Phase 2 Terminated

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00257348 2013-02-08

Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer

Phase 2 Completed

5 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT00118300 2011-07-08

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer

Phase 1 Withdrawn

Gynecologic

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

Clinical Trials

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

KEYVIBE-005

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

IVY

Galunisertib Combined With Capecitabine in Advanced CRC With PM

SMMART Adaptive Clinical Treatment (ACT) Trial

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer